SCHEMBL24227147

SCHEMBL24227147

CC(S)c1c(O)cc(O)cc1O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.39
CYP3A4 P08684 3/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
HPGD P15428 1/20 0.37
EGFR P00533 2/20 0.37
CDK4 P11802 2/20 0.37
CCND1 P24385 2/20 0.37
BACE1 P56817 1/20 0.35
NQO1 P15559 1/20 0.35
ALDH1A1 P00352 1/20 0.33
PTGS1 P23219 1/20 0.33
DRD3 P35462 1/20 0.33
TYR P14679 3/20 0.32
AHR P35869 1/20 0.32
ACHE P22303 1/20 0.32
CA12 O43570 1/20 0.31
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31
CA7 P43166 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9744348 0.78 AHR (0.48) TDP1CYP3A4MEN1KMT2AHPGD
SCHEMBL2979291 0.76 EGFR (0.50) TDP1CYP3A4MEN1KMT2AHPGD
SCHEMBL28880597 0.70 BACE1 (0.44) CYP3A4MEN1KMT2ABACE1ALDH1A1
SCHEMBL20621450 0.70 RXRA (0.46) TDP1CYP3A4MEN1KMT2AHPGD
SCHEMBL29427938 0.70 CYP3A4 (0.43) TDP1CYP3A4MEN1KMT2AHPGD
SCHEMBL16010550 0.70 CYP3A4 (0.43) TDP1CYP3A4MEN1KMT2AHPGD
SCHEMBL19000652 0.69 BACE1 (0.41) TDP1CYP3A4MEN1KMT2AHPGD
SCHEMBL10048630 0.69 EGFR (0.45) TDP1CYP3A4MEN1KMT2AHPGD
SCHEMBL17402434 0.69 AHR (0.37) TDP1CYP3A4MEN1KMT2AHPGD
SCHEMBL28880611 0.69 TYR (0.55) TYRCA12CA1CA2CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11236082-B2 EZH2 inhibitors and uses thereof DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-02-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11236082-B2 EZH2 inhibitors and uses thereof EZH2, EZH1, BMI1 TDP1 2226/4885CYP3A4 4417/4885MEN1 1860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.